major diseases research

284 Pages·2008·4.11 MB·English

MAJOR
DISEASES
RESEARCH
Catalogue of
Research Projects
(2005-2006) in the
Sixth Framework Programme
Volume II
s
e
s
p
o
n
y
s
t
c
e
j
o
r
p
Interested in European research?
Research*eu is our monthly magazine keeping you in touch with main developments
(results, programmes, events, etc.). It is available in English, French, German and Spanish.
A free sample copy or free subscription can be obtained from:
European Commission
Directorate-General for Research
Communication Unit
B-1049 Brussels
Fax [phone]
E-mail: [email protected]
Internet: http://ec.europa.eu/research/research-eu
European Commisssion
Directorate-General for Research
Directorate F – Health
Unit F.2 – Medical and Public Health Research
Contact: Manuel Hallen
European Commission
Offi ce CDMA 2/22
B-1049 Brussels
MAJOR
DISEASES
RESEARCH
Catalogue of
Research Projects
(2005-2006) in the
Sixth Framework Programme
Volume II
Edited by Manuel Hallen
2008 Medical and Public Health Research EUR 23346 EN
Europe Direct is a service to help you fi nd answers
to your questions about the European Union
Freephone number (*):
00 800 6 7 8 9 10 11
(*) Certain mobile telephone operators do not allow access to 00 800 numbers or these calls may be billed.
LEGAL NOTICE
Neither the European Commission nor any person acting on behalf of the Commission
is responsible for the use which might be made of the following information.
The views expressed in this publication are the sole responsibility of the author and do
not necessarily refl ect the views of the European Commission.
A great deal of additional information on the European Union is available on the Internet.
It can be accessed through the Europa server (http://europa.eu.int).
Cataloguing data can be found at the end of this publication.
Luxembourg: Offi ce for Offi cial Publications of the European Communities, 2008

ISBN 978-92-79-08526-0
© European Communities, 2008
Reproduction is authorised provided the source is acknowledged.
Printed in Belgium
PRINTED ON WHITE CHLORINE-FREE PAPER
TABLE OF CONTENTS
INTRODUCTION 7
CARDIOVASCULAR 9 ➞ 44
Cardiogenics 10
CONTICA 13
CVDIMMUNE 15
EUGeneHeart 17
GENECURE 20
HDLomics 22
HeartRepair 24
IMMUNATH 27
InGenious HyperCare 29
NORMACOR 31
PolyALA 33
PROCARDIS 34
PULMOTENSION 36
SOUTH 39
VASOPLUS 42
DIABETES & OBESITY 45 ➞ 57
EuroDia 46
HEPADIP 48
InterAct 51
PREDICTIONS 54
SAVEBETA 56
RARE DISEASES 59 ➞ 78
EURAMY 60
EuroCareCF 62
EuroGrow 65
EURO-Laminopathies 67
HUE-MAN 70
MYASTAID 73
TREAT-NMD 76
3
ANTI-MICROBIAL DRUG RESISTANCE 79 ➞ 110
ACE 80
CRAB 82
DRESP2 84
EACCAD 86
EAR 88
EURESFUN 91
GRACE 94
MagRSA 98
MANASP 100
MOSAR 102
NPARI 105
REBAVAC 107
StaphDynamics 109
BRAIN, NEUROLOGICAL AND PSYCHIATRIC DISEASES 111 ➞ 160
AGLAEA 112
cNEUPRO 114
DB workshop 116
ENINET 118
Enough sleep 120
EPICURE 122
EUSynapse 125
IMAGEN 127
INCF 129
INDABIP 131
INTELLIMAZE 133
MEMORIES 136
NEOBRAIN 138
NEURODYS 141
NeuroproMiSe 143
NovelTune 146
PHECOMP 148
PHOTOLYSIS 150
PNS-EURONET2 152
4
RATstream™ 154
SGENE 157
TAMAHUD 159
HUMAN DEVELOPMENT AND AGEING 161 ➞ 181
ARIG 162
CRESCENDO 164
ECONAG 167
ELAST-AGE 169
EWA 171
LifeSpan 174
PROTEOMAGE 176
RespViruses 179
SENECA 180
CANCER 183 ➞ 265
Anti-tumor targeting 184
Apotherapy 186
BAMOD 188
CancerGrid 190
CANCERIMMUNOTHERAPY 193
CAPPELLA 195
CHEMORES 197
CHILDHOPE 199
CONTICANET 202
DASIM 205
DEPPICT 206
DISMAL 208
E.E.T.-Pipeline 210
EPCRC 212
EPITRON 214
EuroBoNet 216
EuroCSC 218
GenoMEL 220
GROWTHSTOP 222
5
HERMIONE 224
HI-CAM 226
HighReX 228
Immuno-PDT 230
INCA 232
KidsCancerKinome 234
LIGHTS 236
MAMMI 238
MCSCs 240
MMR-related cancer 242
MSCNET 243
NORMOLIFE 245
ONCASYM 247
ONCODEATH 249
OVCAD 251
POLYGENE 253
PROMET 255
TCAC in Cancer 257
TRIDENT 259
TRKCancer 261
Tumor-Host Genomics 262
VITAL 264
ADDITIONAL PROJECTS RELATED TO MAJOR DISEASES 267 ➞ 272
ECRIN-TWG 268
EUROIRON1 271
INDEX BY ACRONYM 274 ➞ 275
FP6 INSTRUMENTS 276 ➞ 277
6
INTRODUCTION
The “Sixth Framework Programme for RTD (FP6 – 2002-2006) of the Five different funding schemes, each with a different objective, were
European Union” has dedicated some € 800 million to supporting research available in FP6 for providing support to research projects. Integrated
in the fi eld of “Major Diseases: Application-orientated Genomic Approaches Projects (IP) and Specifi c Targeted Research Projects (STREP) were aimed
to Medical Knowledge and Technologies”, with the aim of improving the at generating, demonstrating and validating new knowledge through
quality of life and the health of patients in Europe (1) and around the world. research and development. Networks of Excellence (NoE) supported stra-
tegic research coordination through extensive networking. Coordination
The greatest disease burden in Europe is represented by non-communicable Actions (CA) and Specifi c Support Actions (SSA) promoted collaboration
diseases (NCD): a group of conditions that includes cardiovascular disease and coordination of smaller scale projects, and other activities such as
(CVD), cancer, mental health problems, diabetes mellitus, chronic respiratory conferences and studies. In addition, collaboration between industry and
diseases and musculoskeletal conditions. This broad group of disorders; academia was strongly encouraged, in particular the involvement of small
which are linked by common risk factors, underlying determinants and and medium-sized enterprises (SMEs).
opportunities for intervention, cause 86 % of all deaths and 77 % of the
disease burden in Europe. In 2005 the fi rst Volume on project synopses was published, covering
87 projects selected from the fi rst and second call for proposals in
The ultimate objective of any health research funding should, therefore, 2002-2004. This publication is available at ftp://ftp.cordis.europa.eu/
be to reduce instances of, and eventually eliminate these diseases. The pub/lifescihealth/docs/major_catalogue_complet.pdf.
task is huge since conditions such as CVD, neurological disorders and
cancer are highly complex and thus can often be understood and ad- The present Volume 2 of project synopses on “Major Diseases Research”
dressed only by multidisciplinary teams. For more than 25 years, European is a complementary publication featuring an additional 113 projects
Union Framework Programmes have provided fi nancial support to medi- selected under the third and fourth calls for proposals in the afore-
cal and life sciences research, including the training of new scientists. mentioned research areas. The budget of some € 800 million was divided
Europe is fortunate in having an excellent research base and scientists unevenly across funding schemes. Approximately half of the budget went
able to collaborate across national borders, producing top quality results to large integrated projects (IP), which represented less than a quarter of
and a mutual respect of their respective neighbours’ skills and qualities. the number of projects funded. On average, an IP involved 20 partners
with a mean EC contribution of around € 9 million per project. On the
Due to the availability of the full sequence of the human genome and other hand, around one third of the major diseases budget was devoted
many other model organisms at the beginning of the Millennium, the to smaller, specifi c targeted research projects (STREP), which accounted
Sixth Framework Programme placed an emphasis on exploiting the for more than half of the total number of projects supported. These con-
unprecedented opportunities for generating new knowledge. This know- sortia gathered an average number of 10 partners with a mean project
ledge could then be used for the prevention and management of human budget in the region of € 2.5 million.
disease and for advice on living and ageing healthily. Although the pro-
gramme focused primarily on basic research, some areas, such as cancer, The structure of this “Volume 2” follows the structure of the fi rst
were more directed towards translational research. This enabled the basic Volume, and brief reference is made to all 87 projects described in the
research already completed to be transferred to medical and therapeutic fi rst Volume, including complete and coherent “Tables of Contents” and
applications. “Indices” arranged by project acronym, contract number and name of
project coordinator. This allows us to provide the full picture of all
Close to 850 research proposals were evaluated by peer review and some research funded under the Sixth Framework Programme in this area.
200 projects have been funded across the seven priority areas of: Each research area has a chapter devoted to it and is introduced by the
• Cardiovascular disease current Scientifi c Offi cer(s) in charge.
• Diabetes
• Rare diseases We would like to acknowledge the Scientifi c Offi cers in charge, praising
• Anti-microbial drug resistance their competence, professionalism and commitment as well as the
• Brain, neurological and psychiatric diseases invaluable input provided by the previous Scientifi c Offi cers in charge
• Human development and ageing, and (Philippe Cupers, Mary Fitzgerald, Elmar Nimmesgern, Jürgen Sautter and
• Cancer Christian Wimmer). We would also like to acknowledge Anna Lönnroth,
Deputy Head of Unit “Infectious Diseases” and the preceding Head of
An average success rate of around 25 % was achieved for proposals across Unit “Major Diseases”, Alain Vanvossel.
all four calls. This rate varied depending on the type of funding scheme
and area of research, with a lower success rate for cancer topics overall
(between 18 and 22 %), but a higher rate for small projects (coordination
actions and specifi c support actions) and Networks of Excellence (above
35 % of successful proposals).
Maria Vidal-Ragout Manuel Hallen
(1) WHO Europe fact sheet EURO/03/06, www.euro.who.int/document/mediacentre/fs0306e.pdf Deputy Head of Unit Head of Unit
7